No Evidence of an Association between Transient HIV Viremia (“Blips”) and Lower Adherence to the Antiretroviral Medication Regimen

Open Access
Publisher Website
Google Scholar
Abstract
Background. Transient human immunodeficiency virus (HIV) viremia, a common phenomenon among patients taking antiretroviral therapy, is often attributed to lapses in adherence to the medication regimen. We investigated this relationship in a prospective observational cohort of 128 patients initiating a new regimen. Methods. A case of transient viremia was defined as an HIV RNA level of 40–1000 copies/mL (“blip”) sandwiched between 2 months of HIV RNA levels Results. Among the 28 case subjects, mean CAS-measured adherence did not decrease before transient viremia; adherence during the pre, blip, and post periods were 86%, 84%, and 80%, respectively. Control subjects had lower adherence levels during the corresponding 3 months (77%, 79%, and 75%, respectively; P = .046). Among the 19 patients able to serve as their own controls, CAS-measured adherence was higher during the period of transient viremia than during control periods (P = .01). Similar relationships were found when comparing only electronically measured adherence on a week-wise basis. There were no significant differences in dose-timing error between case subjects and control subjects. Conclusions. We found no evidence that transient HIV viremia is associated with decreases in adherence or differences in dose-timing. Other etiologies for transient viremia should be evaluated.

This publication has 0 references indexed in Scilit: